Testing Anti-Trypanosoma cruzi Compounds for Chagas Disease
Author Information
Author(s): Andriani Grasiella, Chessler Anne-Danielle C., Courtemanche Gilles, Burleigh Barbara A., Rodriguez Ana
Primary Institution: New York University School of Medicine
Hypothesis
Can high throughput screening identify effective compounds against Trypanosoma cruzi?
Conclusion
Two compounds significantly reduced T. cruzi infection in a mouse model after five days of treatment.
Supporting Evidence
- 23 compounds were selected from high throughput screening for further analysis.
- Half of the compounds confirmed anti-T. cruzi activity in vitro.
- Two compounds reduced T. cruzi infection in mice by more than 90%.
Takeaway
Scientists are looking for new medicines to help treat Chagas disease, and they found two promising compounds that work really well in mice.
Methodology
The study involved high throughput screening to select compounds, followed by in vitro and in vivo testing in mice.
Limitations
Some compounds that showed activity in initial tests did not perform well in vivo, indicating a need for further validation.
Participant Demographics
Balb/c mice were used for in vivo testing.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website